Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent...

Bullseye Chart: The Psychedelic Drug Development Pipeline

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics...

Opinions | Australia’s Rescheduling of MDMA and Psilocybin a Welcome First...

Panel: Neuroimaging in Psychedelic Research

PT387 – Psychedelic Ethics & Self-Reflexivity and Proposition 122 Conflict &...

Optimi Health Submits Phase I Clinical Trial Application Combining The Use...

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New...

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal...

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Load more